Jim Mullen, Editas Medicine CEO
February 22, 2021 02:13 PM EST
People

Jim Mullen won a $20M op­tion pack­age when he switched from chair­man to the CEO job at Ed­i­tas — and it's all tied to per­for­mance

John Carroll

Editor & Founder

The last time James Mullen ran a bio­phar­ma com­pa­ny, he was roast­ed by Carl Ic­ahn for draw­ing tens of mil­lions of dol­lars in com­pen­sa­tion at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times